Glucagon-Like Peptide 1

Glucolipotoxicity and GLP-1 secretion
Jung-Hee Hong, Dae-Hee Kim, Moon-Kyu Lee

BMJ Open Diabetes Research and Care Feb 2021, 9 (1) e001905; DOI: 10.1136/bmjdrc-2020-001905
Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
Elin Manell, Emmi Puuvuori, Anna Svensson, Irina Velikyan, Gry Hulsart-Billström, Patricia Hedenqvist, Jens Juul Holst, Marianne Jensen Waern, Olof Eriksson

BMJ Open Diabetes Research and Care Apr 2021, 9 (1) e002083; DOI: 10.1136/bmjdrc-2020-002083
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli, Ike Ogbaa, John Stewart, Linda Morrow

BMJ Open Diabetes Research and Care Jun 2021, 9 (1) e002208; DOI: 10.1136/bmjdrc-2021-002208
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
Emilie H Zobel, Asger Wretlind, Rasmus S Ripa, Viktor Rotbain Curovic, Bernt J von Scholten, Tommi Suvitaival, Tine W Hansen, Andreas Kjær, Cristina Legido-Quigley, Peter Rossing

BMJ Open Diabetes Research and Care Sep 2021, 9 (1) e002395; DOI: 10.1136/bmjdrc-2021-002395
Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
Wenhuan Feng, Weimin Wang, Ran Meng, Guangyu Wu, Minlu Zhang, Xia Zhang, Huiqiu Yin, Dalong Zhu

BMJ Open Diabetes Research and Care Aug 2021, 9 (1) e002290; DOI: 10.1136/bmjdrc-2021-002290
Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis
Anastasia-Stefania Alexopoulos, Alice Parish, Maren Olsen, Bryan C Batch, Cynthia Moylan, Matthew J Crowley

BMJ Open Diabetes Research and Care Nov 2023, 11 (6) e003763; DOI: 10.1136/bmjdrc-2023-003763
Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis
Dominik Wollenhaupt, Jannik Wolters, Mirna Abd El Aziz, Michael A Nauck

BMJ Open Diabetes Research and Care Jul 2023, 11 (4) e003296; DOI: 10.1136/bmjdrc-2022-003296
Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
Stephen C Bain, Bendix Carstensen, Liselotte Hyveled, Stephanie Seremetis, Frederik Flindt Kreiner, Hanan Amadid, Alice Clark

BMJ Open Diabetes Research and Care Jun 2023, 11 (3) e003300; DOI: 10.1136/bmjdrc-2022-003300
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
John B Buse, Helene Nordahl Christensen, Brian J Harty, Julie Mitchell, Benjamin P Soule, Emily Zacherle, Mark Cziraky, Vincent J Willey

BMJ Open Diabetes Research and Care May 2023, 11 (3) e003206; DOI: 10.1136/bmjdrc-2022-003206
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H Sorli, Alka Shaunik, Kun-Ho Yoon

BMJ Open Diabetes Research and Care Jan 2022, 10 (1) e002207; DOI: 10.1136/bmjdrc-2021-002207

Main menu

Glucagon-Like Peptide 1

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Glucagon-Like Peptide 1

Pages